Infectious Infectious Disorders of the Disorders of the Lung Parenchyma Lung Parenchyma Matthew L. Paden, MD Matthew L. Paden, MD Pediatric Critical Care Pediatric Critical Care Fellow Fellow Emory University Emory University Children’s Healthcare of Children’s Healthcare of Atlanta at Egleston Atlanta at Egleston
Infectious Disorders of the Lung Parenchyma. Matthew L. Paden, MD Pediatric Critical Care Fellow Emory University Children’s Healthcare of Atlanta at Egleston. Objectives. Worldwide epidemiology of the problem Review common etiologies Discuss empirical and disease specific treatment. - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Infectious Infectious Disorders of the Disorders of the
Lung Lung ParenchymaParenchyma
Matthew L. Paden, MDMatthew L. Paden, MDPediatric Critical Care FellowPediatric Critical Care Fellow
Emory UniversityEmory UniversityChildren’s Healthcare of Atlanta Children’s Healthcare of Atlanta
at Eglestonat Egleston
ObjectivesObjectives
Worldwide epidemiology of the Worldwide epidemiology of the problemproblem
Review common etiologiesReview common etiologies Discuss empirical and disease Discuss empirical and disease
specific treatmentspecific treatment
EpidemiologyEpidemiology World wideWorld wide
Leading cause of Leading cause of death in childrendeath in children
More than AIDS, More than AIDS, malaria, and measles malaria, and measles combinedcombined
Most deaths in < 5 yoMost deaths in < 5 yo United statesUnited states
33rdrd leading cause of leading cause of hospitalization for hospitalization for kidskids
2% of deaths (5% 2% of deaths (5% including neonates)including neonates)
Less than 1 yo, get any formula – 5 X Less than 1 yo, get any formula – 5 X increased risk of death from pneumoniaincreased risk of death from pneumonia
Zinc supplementationZinc supplementation
PreventionPrevention
ImmunizationImmunization Measles –Measles –
Pneumonia is what they die of – often super-Pneumonia is what they die of – often super-infectioninfection
World-wide coverage rate – 76% in 2004World-wide coverage rate – 76% in 2004 Still having 30-40 million cases a yearStill having 30-40 million cases a year
HIB –HIB – 2-3 million cases of severe disease a year2-3 million cases of severe disease a year In 2003, developed world coverage – 92%In 2003, developed world coverage – 92% Developing world – 42%Developing world – 42% Least developed countries – 8%Least developed countries – 8%
7 –valent vaccine (Prevnar) in the US7 –valent vaccine (Prevnar) in the US 9, 11, or 13 valent vaccine for the rest of 9, 11, or 13 valent vaccine for the rest of
the worldthe world Gambia – 17,000 childrenGambia – 17,000 children
37% reduction in pneumonia37% reduction in pneumonia 15% reduction in hospitalization15% reduction in hospitalization 16% reduction in mortality16% reduction in mortality
Costs involvedCosts involved
More than 1 million deaths a year can be More than 1 million deaths a year can be prevented with treatment and preventionprevented with treatment and prevention
600,000 lives saved by just treatment alone600,000 lives saved by just treatment alone Cost analysisCost analysis
$ 600 million total cost including :$ 600 million total cost including : Cost of antibioticsCost of antibiotics Cost of hospital staysCost of hospital stays Increasing training of health care staffIncreasing training of health care staff Increasing physical plants to take care of these Increasing physical plants to take care of these
patients patients
Costs involvedCosts involved
Those costs inflated by Mexico and Those costs inflated by Mexico and BrazilBrazil
85% of deaths are in sub-Saharan 85% of deaths are in sub-Saharan Africa and southeast AsiaAfrica and southeast Asia $200 million dollars will expand $200 million dollars will expand
coverage to those regions only and coverage to those regions only and potentially fix 85% of the problem potentially fix 85% of the problem
Potential solutionsPotential solutions One F-22 fighter - $183 millionOne F-22 fighter - $183 million 1997-2003, Defense Department purchased and then left
unused approximately 270,000 fully refundable commercial airline tickets at a total cost of $100 million.
$4,000,000 for the Northern Line Extension A direct 82 mile train route from North Pole (pop. 1,778 in
2005) to Delta Junction (pop. 840 in 2000) $9,500,000 for the Extended Cold Weather Clothing
System $8,000,000 added by the Senate for special assistance
DOD Dependents Education. $5,500,000 for The Ernest Gallo Clinic and Research
Center at (USCF) to study basic neuroscience and the effects of alcohol and drug abuse on the brain.”
$1,650,000 to improve the shelf life of vegetables “This project will help our troops in the field get fresh tomatoes…”
DiagnosisDiagnosis
TachypneaTachypnea Sensitive but not specificSensitive but not specific
Surveillance dataSurveillance data 56% PCN resistant56% PCN resistant
Geographically-based evaluation of multi-drug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003-2004). Int J Antimicrob Agents. 2006 Dec;28(6):525-31.
2006 CHOA Data2006 CHOA Data
OrganisOrganismm
VanVancc
CTX ICTX I CTX RCTX R PCN IPCN I PCN PCN RR
ECH ECH Strep Strep pneumopneumo
0%0% 21/1421/14%%
20/6 20/6 %%
14 %14 % 46 %46 %
SRH SRH Strep Strep pneumopneumo
0 %0 % 26/9 26/9 %%
7/8 %7/8 % 34 %34 % 31 %31 %
Percent of organisms tested that have intermediate or resistant sensitivity patterns
Treatment – Strep Treatment – Strep pneumopneumo
Mechanism of resistance – Mechanism of resistance – PCN and Cephalosporins – change in PCN and Cephalosporins – change in
Empiric : 3Empiric : 3rdrd generation generation cephalosporin + vancomycin until cephalosporin + vancomycin until sensitivities are confirmedsensitivities are confirmed
EtiologiesEtiologies
Staphylococcus aureusStaphylococcus aureus Common cause of ventilator associated Common cause of ventilator associated
and nosocomial pneumoniaand nosocomial pneumonia Community acquired disease usually Community acquired disease usually
coincident with viral infection coincident with viral infection (influenza)(influenza) Viral hemagglutinins – inhibit neutrophil Viral hemagglutinins – inhibit neutrophil
and monocyte activationand monocyte activation Gram stain – gram positive cocci in Gram stain – gram positive cocci in
Treatment has changed over the past 5 Treatment has changed over the past 5 years with emergence of caMRSAyears with emergence of caMRSA
Empiric therapy with VancomycinEmpiric therapy with Vancomycin VISA (1996, Japan, 1997 US) VISA (1996, Japan, 1997 US)
Mechanism – thickening of cell membrane – decreased Mechanism – thickening of cell membrane – decreased penetration of vancomycin – unclear mechanism penetration of vancomycin – unclear mechanism
VRSA (2002, US)VRSA (2002, US) Mechanism – VanA from enterococcus – changes d-Mechanism – VanA from enterococcus – changes d-
alanine, d-alanine terminus to d-alanine, d-lactate – alanine, d-alanine terminus to d-alanine, d-lactate – reduces affinity by 1,000 foldreduces affinity by 1,000 fold
VDSA VDSA
2006 CHOA Data2006 CHOA Data
OrganisOrganismm
VanVancc
ClindClinda*a*
BactriBactrimm
RifampRifampinin
GentGent
ECH ECH MRSAMRSA
0%0% 14%14% 1 %1 % 1 %1 % 1 %1 %
SRH SRH MRSAMRSA
0 %0 % 13 %13 % 1 %1 % 1 %1 % 3 %3 %
• ECH total % MRSA 53% SRH total % MRSA 51%
* Not adjusted for inducible resistance
Staph Aureus treatmentStaph Aureus treatment
Get off Vancomycin if MSSAGet off Vancomycin if MSSA MSSA much more susceptible to NafcillinMSSA much more susceptible to Nafcillin Use of Vancomycin or first-generation Use of Vancomycin or first-generation
Cephalosporins for the treatment of hemodialysis-Cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Staphylococcus aureus bacteremia. Clin Infect Dis. 2007 Jan 15;44(2):190-6.Dis. 2007 Jan 15;44(2):190-6.
Treatment failure - Vancomycin 31.2% vs. Ancef 13% ; Treatment failure - Vancomycin 31.2% vs. Ancef 13% ; p=.02p=.02
Multivariable analysis - factors independently associated Multivariable analysis - factors independently associated with treatment failure included Vancomycin use (odds with treatment failure included Vancomycin use (odds ratio, 3.53; 95% confidence interval, 1.15-13.45) ratio, 3.53; 95% confidence interval, 1.15-13.45)
Staph aureus treatmentStaph aureus treatment Get off Vancomycin if MSSAGet off Vancomycin if MSSA
Staphylococcus aureus bacteremia and endocarditis: Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am Heart J. 2004 Mar;147(3):536-9. aureus bacteremia. Am Heart J. 2004 Mar;147(3):536-9.
MSSA bacteremia is associated with higher rates of MSSA bacteremia is associated with higher rates of endocarditis than MRSA. endocarditis than MRSA.
Comparative activity of cloxacillin and vancomycin Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus against methicillin-susceptible Staphylococcus aureus experimental endocarditis.experimental endocarditis.J Antimicrob Chemother. 2006 Nov;58(5):1066-9.J Antimicrob Chemother. 2006 Nov;58(5):1066-9.
Cloxacillin produced a greater decrease in the number of Cloxacillin produced a greater decrease in the number of staphylococci than vancomycin staphylococci than vancomycin
41% of rabbits had sterile vegetations in comparison with 41% of rabbits had sterile vegetations in comparison with 0% with vancomycin (p=0.035)0% with vancomycin (p=0.035)
New horizonsNew horizons Anti-MRSA beta-lactams in development, with a Anti-MRSA beta-lactams in development, with a
focus on ceftobiprole: the first anti-MRSA beta-focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs. 2007 Apr;16(4):419-29. Opin Investig Drugs. 2007 Apr;16(4):419-29. Investigational beta-lactam antibiotic against Investigational beta-lactam antibiotic against
methicillin-resistant staphylococci, enterococcus methicillin-resistant staphylococci, enterococcus faecalis, penicillin-resistant streptococci and many faecalis, penicillin-resistant streptococci and many Gram-negative pathogens. Gram-negative pathogens.
Completed Phase III therapeutic trialsCompleted Phase III therapeutic trials PPI0903 - injectable pro-drug of a broad-PPI0903 - injectable pro-drug of a broad-
spectrum cephalosporin with anti-MRSA activityspectrum cephalosporin with anti-MRSA activity RO4908643 - a carbapenem with anti-MRSA RO4908643 - a carbapenem with anti-MRSA
activityactivity
EtiologiesEtiologies
Pseudomonas aeruginosaPseudomonas aeruginosa Common cause of bacterial nosocomial Common cause of bacterial nosocomial
pneumoniapneumonia More common in CF, tracheostomy More common in CF, tracheostomy
dependant, or immunocompromiseddependant, or immunocompromised Oxidase positive gram negative rodOxidase positive gram negative rod
lactamaselactamase Implication – serious or life-threatening Implication – serious or life-threatening
infections should not be treated with an anti-infections should not be treated with an anti-pseudomonal synthetic pseudomonal synthetic penicillin/cephalosporin/carbapenem alonepenicillin/cephalosporin/carbapenem alone
Empiric therapy – anti-pseudomonal PCN Empiric therapy – anti-pseudomonal PCN + an aminoglycoside+ an aminoglycoside Role of monotherapy has not been well defined.Role of monotherapy has not been well defined.
Mechanism of ActionMechanism of Action Inhibits bacterial cell wall synthesis by binding Inhibits bacterial cell wall synthesis by binding
to one or more of the penicillin-binding proteinsto one or more of the penicillin-binding proteins Inhibits the final transpeptidation step of Inhibits the final transpeptidation step of
peptidoglycan synthesis in bacterial cell walls peptidoglycan synthesis in bacterial cell walls Clavulanate and tazobactam prevents Clavulanate and tazobactam prevents
degradation of the PCN by binding to beta-degradation of the PCN by binding to beta-lactamases lactamases
Ceftazidime – 2Ceftazidime – 2ndnd generation with generation with pseudomonas activitypseudomonas activity
Pseudomonas treatmentPseudomonas treatment
Antibiotic choicesAntibiotic choices 44thth generation cephalosporin – cefepime generation cephalosporin – cefepime Mechanism of Action Mechanism of Action
Inhibits bacterial cell wall synthesis by Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding to one or more of the penicillin-binding proteinsbinding proteins
Inhibits the final transpeptidation step of Inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell peptidoglycan synthesis in bacterial cell walls walls
Antibiotic choicesAntibiotic choices Carbapenems – imipenem-cilastatin or Carbapenems – imipenem-cilastatin or
meropenemmeropenem Mechanism of Action Mechanism of Action
Inhibits cell wall synthesis by binding to Inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) with its penicillin-binding proteins (PBPs) with its strongest affinities for PBPs 2, 3 and 4 of strongest affinities for PBPs 2, 3 and 4 of E. E. colicoli and and P. aeruginosaP. aeruginosa and PBPs 1, 2 and 4 of and PBPs 1, 2 and 4 of S. aureusS. aureus
Meropenem reduces valproate levels by Meropenem reduces valproate levels by ~40% ~40%
Antibiotic choicesAntibiotic choices AztreonamAztreonam Mechanism of ActionMechanism of Action
Binds to penicillin-binding protein 3 which Binds to penicillin-binding protein 3 which produces filamentation of the bacterium produces filamentation of the bacterium inhibiting bacterial cell wall synthesis and inhibiting bacterial cell wall synthesis and causing cell wall destruction causing cell wall destruction
levofloxacin, etc.levofloxacin, etc. Mechanism of Action Mechanism of Action
Inhibits DNA-gyrase and topoisomerase IV Inhibits DNA-gyrase and topoisomerase IV in susceptible organisms; inhibits relaxation in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of supercoiled DNA and promotes breakage of double-stranded DNA of double-stranded DNA
gentamicin, tobramycingentamicin, tobramycin Mechanism of Action Mechanism of Action
Inhibits cellular initiation of bacterial Inhibits cellular initiation of bacterial protein synthesis by binding to 30S and 50S protein synthesis by binding to 30S and 50S ribosomal subunits resulting in a defective ribosomal subunits resulting in a defective bacterial cell membranebacterial cell membrane
Common cause of pneumonia in Common cause of pneumonia in school age childrenschool age children Persistent cough (for weeks after Persistent cough (for weeks after
Mycoplasma – clinical picture + Mycoplasma – clinical picture + serologic testingserologic testing Cold agglutinins are not specificCold agglutinins are not specific Complications – arthritis, hemolysis, Complications – arthritis, hemolysis,
pericardial effusions, myocarditis, pericardial effusions, myocarditis, encephalitis, Stevens-Johnson syndromeencephalitis, Stevens-Johnson syndrome Antibiotic therapy has not been conclusively Antibiotic therapy has not been conclusively
shown to help non-pulmonary shown to help non-pulmonary manifestationsmanifestations
Legionella pneumophiliaLegionella pneumophilia Severe disease in immunocompromisedSevere disease in immunocompromised
Respiratory failure, pericarditisRespiratory failure, pericarditis Classic history triggers – exposure to Classic history triggers – exposure to
travel, hot tubs, or hospitalizationtravel, hot tubs, or hospitalization DFA, culture, and serology availableDFA, culture, and serology available Urinary antigen – good sensitivity and Urinary antigen – good sensitivity and
Mechanism of Action Mechanism of Action Inhibits bacterial RNA-dependent Inhibits bacterial RNA-dependent
protein synthesis by binding to the 50S protein synthesis by binding to the 50S ribosomal subunit which results in the ribosomal subunit which results in the blockage of transpeptidation blockage of transpeptidation
If fails traditional management (steroids, If fails traditional management (steroids, oxygen, epinephrine, heliox, etc.) and is oxygen, epinephrine, heliox, etc.) and is intubated get endotracheal aspirate for intubated get endotracheal aspirate for bacterial superinfectionbacterial superinfection
Steroids – RSV alone, no efficacy in Steroids – RSV alone, no efficacy in reducing stayreducing stay
Ribivirin – only FDA approved drug for RSVRibivirin – only FDA approved drug for RSV Many complications and expensiveMany complications and expensive May have a role in the immunocompromisedMay have a role in the immunocompromised
RSV PneumoniaRSV Pneumonia Similar presentation as bronchiolitisSimilar presentation as bronchiolitis Different pathophysiology – alveolar Different pathophysiology – alveolar
filling and consolidationfilling and consolidation CXRCXR
Discrete infiltrate and lack of hyperinflationDiscrete infiltrate and lack of hyperinflation Greater degree of hypoxiaGreater degree of hypoxia More likely to progress to ARDSMore likely to progress to ARDS
RSV ApneaRSV Apnea Not well describedNot well described More common with increasing More common with increasing
prematurityprematurity Polysomnography implies it is central Polysomnography implies it is central
apneaapnea Pathophysiology – signaling from Pathophysiology – signaling from
pulmonary nerves through the GABA and pulmonary nerves through the GABA and substance P pathwayssubstance P pathways Pediatr Res. 2005 Jun;57(6):819-25.Pediatr Res. 2005 Jun;57(6):819-25.
Enveloped, single stranded, negative Enveloped, single stranded, negative polarity RNA paramyxoviruspolarity RNA paramyxovirus
Similar presentations to RSVSimilar presentations to RSV Viral culture is gold standardViral culture is gold standard DFA or PCR availableDFA or PCR available 4 different virus types4 different virus types
Type 1 epidemic every other yearType 1 epidemic every other year
Neuroaminidase – cleaves sialic acid Neuroaminidase – cleaves sialic acid residues once virus has multiplied in the residues once virus has multiplied in the cell allowing viral spreadcell allowing viral spread
Influenza Viral Life CycleInfluenza Viral Life Cycle
Influenza diagnosisInfluenza diagnosis
Clinical markersClinical markers Other manifestationsOther manifestations
Viral culture is gold standardViral culture is gold standard DFA, PCR, and rapid immunoassays DFA, PCR, and rapid immunoassays
availableavailable
Influenza treatmentInfluenza treatment
Amantidine or rimantidineAmantidine or rimantidine Inhibits influenza M2 proteins and Inhibits influenza M2 proteins and
prevent viral uncoatingprevent viral uncoating Need to give early or no benefitNeed to give early or no benefit Resistance is documentedResistance is documented
Oseltamivir and zanamivirOseltamivir and zanamivir Neuroaminidase inhibitors Neuroaminidase inhibitors
Adenovirus diagnosisAdenovirus diagnosis Specifically types 3 and 7Specifically types 3 and 7 Rapidly evolving life threatening Rapidly evolving life threatening
pneumonia with necrosis, pulmonary pneumonia with necrosis, pulmonary hemorrhage and bronchiolitis obliteranshemorrhage and bronchiolitis obliterans
Survival dependant on degree of injurySurvival dependant on degree of injury Viral culture is gold standardViral culture is gold standard DFA, PCR, rapid ELISA are availableDFA, PCR, rapid ELISA are available ECLS an optionECLS an option
Extracorporeal life support for the treatment of Extracorporeal life support for the treatment of viral pneumonia: collective experience from the viral pneumonia: collective experience from the ELSO registry. Extracorporeal Life Support ELSO registry. Extracorporeal Life Support Organization. J Pediatr Surg. 1997 Organization. J Pediatr Surg. 1997 Feb;32(2):232-6.Feb;32(2):232-6.
Symptoms very similar to RSV (cough 90%; Symptoms very similar to RSV (cough 90%; dyspnea 83%; coryza 88%; fever 52-92%)dyspnea 83%; coryza 88%; fever 52-92%)
Can cause severe disease in BMT patientsCan cause severe disease in BMT patients PCR based diagnosis at this pointPCR based diagnosis at this point Supportive treatmentSupportive treatment
A negative sense, single stranded RNA A negative sense, single stranded RNA virus of the bunyaviridae familyvirus of the bunyaviridae family
Multiple different viruses worldwideMultiple different viruses worldwide Four corners region - Sin Nombre virusFour corners region - Sin Nombre virus All other bunyaviridae have arthropod All other bunyaviridae have arthropod
vectorsvectors Hantavirus – vector is the deer mouseHantavirus – vector is the deer mouse
8% of hantavirus infections in US are 8% of hantavirus infections in US are childrenchildren 33% mortality (similar to adults)33% mortality (similar to adults)
Hantavirus infectionHantavirus infection
Exposure/Travel historyExposure/Travel history Clinical syndromeClinical syndrome
Laboratory syndromeLaboratory syndrome HemoconcentrationHemoconcentration ThrombocytopeniaThrombocytopenia LeukocytosisLeukocytosis Absence of granules in neutrophilsAbsence of granules in neutrophils Immunoblasts on smearImmunoblasts on smear
Hantavirus diagnosisHantavirus diagnosis
Laboratory syndromeLaboratory syndrome Testing via serologies, Testing via serologies,
immunohistochemistry, and rapid RNA immunohistochemistry, and rapid RNA PCRPCR
All via New Mexico/CDCAll via New Mexico/CDC
Treatment – Treatment – Study with IV Ribavirin via UNM/CDCStudy with IV Ribavirin via UNM/CDC SupportiveSupportive
Hantavirus treatmentHantavirus treatment
Above all – Consultation with experts Above all – Consultation with experts at University of New Mexico and CDCat University of New Mexico and CDC
From CDC Website :From CDC Website : Take-home Message for Care Take-home Message for Care
ProvidersProviders Rapid transfer to ICURapid transfer to ICUCareful monitoringCareful monitoringFluid balanceFluid balanceElectrolyte balance Electrolyte balance Blood pressure Blood pressure
Hantavirus treatmentHantavirus treatment
Management with Swan-Ganz catheter Management with Swan-Ganz catheter essentialessential In contrast to septic shock, HPS patients In contrast to septic shock, HPS patients
have a low cardiac output with a raised have a low cardiac output with a raised systemic vascular resistance. systemic vascular resistance.
Titrate fluid to keep wedge pressure to <12Titrate fluid to keep wedge pressure to <12 Poor prognostic indicators include a plasma Poor prognostic indicators include a plasma
lactate of greater than 4.0 mmol/L or a lactate of greater than 4.0 mmol/L or a cardiac index of less than 2.2 L/min/m2cardiac index of less than 2.2 L/min/m2
Whilst pulmonary edema and pleural Whilst pulmonary edema and pleural effusions are common, multiorgan effusions are common, multiorgan dysfunction syndrome is rarely seen. dysfunction syndrome is rarely seen.
Hantavirus treatmentHantavirus treatment
Prior to the use of extracorporeal Prior to the use of extracorporeal membrane oxygenation (ECMO) as a membrane oxygenation (ECMO) as a rescue therapy, a cardiac index of less rescue therapy, a cardiac index of less than 2.5 L/min/m2 predicted 100% than 2.5 L/min/m2 predicted 100% mortality rate.mortality rate.
Essentially a disease of immuno-Essentially a disease of immuno-compromisedcompromised
Common upper airway and oral floraCommon upper airway and oral flora Colonization vs. infectionColonization vs. infection
Translocation across the gut -> Translocation across the gut -> hematogenous spread to the lungs is hematogenous spread to the lungs is another source in neutropenic another source in neutropenic patientspatients
Multiple speciesMultiple species C. albicans C. albicans
Most commonMost common Quickest of the yeast to be identified – Quickest of the yeast to be identified –
candida chrome agar (green color change)candida chrome agar (green color change) C. parapsilosisC. parapsilosis
Second most common at ECHSecond most common at ECH C. glabrata, krusei, lusitanieaC. glabrata, krusei, lusitaniea
More rare, but the ones to worry aboutMore rare, but the ones to worry about
Antifungal TherapyAntifungal Therapy
Not a lot of good, large number Not a lot of good, large number trials in pediatric immuno-trials in pediatric immuno-suppressed patientssuppressed patients
Even less in treating pneumoniaEven less in treating pneumonia Assume systemic spread in neutropenic Assume systemic spread in neutropenic
patientspatients
Antifungal TherapyAntifungal Therapy Mostly Mostly C. albicansC. albicans fungemia in non-neutropenics fungemia in non-neutropenics Flu (400/d) vs. AmB (0.5-0.6 mg/kg/d). Flu (400/d) vs. AmB (0.5-0.6 mg/kg/d). %Success:%Success:
Randomized, N=206, Flu 70%, AmB 79%, Randomized, N=206, Flu 70%, AmB 79%, PP = 0.22 = 0.22 Randomized, N=103, Flu 56%, AmB 60%, Randomized, N=103, Flu 56%, AmB 60%, PP = 0.80 = 0.80 Observational, N=294, Flu 73%, AmB 69%, Observational, N=294, Flu 73%, AmB 69%, PP = 0.58 = 0.58 Observational, N=479, Flu 71%, AmB 73%, Observational, N=479, Flu 71%, AmB 73%, PP > 0.38 > 0.38
ABLC (5 mg/kg/d) vs. AmB (0.6-1 mg/kg/d)ABLC (5 mg/kg/d) vs. AmB (0.6-1 mg/kg/d) Randomized, N=194, ABLC 65%, AmB 61%, Randomized, N=194, ABLC 65%, AmB 61%, PP = 0.64 = 0.64
Large areas of pulmonary necrosisLarge areas of pulmonary necrosis Can look like staphCan look like staph
Necrosis is because of direct blood Necrosis is because of direct blood vessel invasion by the organism and vessel invasion by the organism and subsequent thrombosissubsequent thrombosis SAME PHYSIOLOGY AS A SAME PHYSIOLOGY AS A
PULMONARY EMBOLUSPULMONARY EMBOLUS Wedge shaped emboli seen on CXRWedge shaped emboli seen on CXR Right heart strain less oftenRight heart strain less often
TB diagnosisTB diagnosis Aerobic acid-fast bacilliAerobic acid-fast bacilli High index of suspicionHigh index of suspicion Exposure/risk factor history is keyExposure/risk factor history is key
Known TB casesKnown TB cases Incarceration (jail/prison)Incarceration (jail/prison) Health care workersHealth care workers Homeless/Community shelterHomeless/Community shelter Immuno-compromisedImmuno-compromised Travel to/visitation from endemic areas Travel to/visitation from endemic areas
(Grady)(Grady) Ask about BCG in immigrantsAsk about BCG in immigrants
TB diagnosisTB diagnosis
Recovery from culture is gold Recovery from culture is gold standardstandard AFB stain and cultureAFB stain and culture
PCR availablePCR available
TB TreatmentTB Treatment Get ID involved for recs and follow-upGet ID involved for recs and follow-up Isolation in negative pressure roomIsolation in negative pressure room
Patient with surgical mask for any transportPatient with surgical mask for any transport Parents to get CXR (surgical mask)Parents to get CXR (surgical mask)
““When determining TB status on adult family When determining TB status on adult family members of inpatients with diagnosed or members of inpatients with diagnosed or strongly suspected TB, external diagnostic strongly suspected TB, external diagnostic resources (private physician, health department) resources (private physician, health department) are considered first.”are considered first.”
““When circumstances do not allow for this, When circumstances do not allow for this, Children’s will provide diagnostic services only Children’s will provide diagnostic services only and refer, if needed, for treatment of disease.”and refer, if needed, for treatment of disease.”
Write an order – parents register – pay or SW - Write an order – parents register – pay or SW - get CXR – Emory radiologists read itget CXR – Emory radiologists read it